SPTX — Seaport Therapeutics, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 2042347 ·
Last close
$20.46
Market Cap
$1.10B
52W High
$23.00
52W Low
$14.85
ADV30
197,616
Next earnings
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -27,543,000 -25,408,000 227,673,000 52,909,000 343,294,000
Mar 2025 0 -16,185,000 -13,125,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-40,377,000
Investing CF
$-197,701,000
Financing CF
$-783,000
CapEx
$-54,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.82
As of
2026-06-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-139,517,000
Inventory
Receivables
$3,277,000
ST Investments
$129,696,000
EBIT TTM
$-43,728,000
Pretax Income TTM
$-37,983,000
Interest Exp TTM
Analysts
4

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -87,294,000 -74,881,000 249,009,000 341,554,000 -77,942,000
Dec 2024 0 -52,416,000 -46,879,000 315,777,000 340,626,000 -29,629,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-2.47

Peers — same industry

TickerNameMarket CapLastDaily %
WVE Wave Life Sciences Ltd. $1.09B $5.51
CRVS Corvus Pharmaceuticals, Inc. $1.12B $13.26
SVRA Savara Inc $1.12B $5.46
FBIOP Fortress Biotech, Inc. $1.07B $18.88
IVA Inventiva S.A. $1.06B $4.48

News headlines (Yahoo Finance, 1h cache)

Assessing Seaport Therapeutics (SPTX) Valuation After Its Recent 10.2% One Day Share Price Move
2026-05-04 07:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.